Global $4 Billion Gamma Delta T Cell Cancer Therapy Market Opportunity & Clinical Trials Insights, 2021-2026 - ResearchAndMarkets.com

·4 min read

The "Global Gamma Delta T Cell Cancer Therapy Opportunity & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

The recent clinical success of chimeric antigen receptor in the management of hematological malignancies has clearly led to the explosion in the field of adoptive cell therapy for cancer. Researchers are currently putting efforts for the translation of this exciting technology in solid tumors and the development of allogeneic off the shelf therapies.

Over the past few years, the idea of immunotherapy of ability to manipulate immune cells in targeting tumor cells is gaining momentum in field of cancer therapeutics. Since then scientists have developed a wide range of potential candidates which has shown encouraging results in the management of cancer.

With the progress in biotechnology researchers were able to identify gamma delta T cells which have potential role in cancer immunosurveillance and have the potential to overcome the challenges in adoptive cell therapy. The cells have both innate and adaptive like properties, thus bridging between the adaptive and innate immunity. Furthermore, these subsets of cells produce different cytokines, chemokine and growth factors which help in generating immune response against the tumor cells.

Since their identification, gamma delta T cells are attractive candidates for the adoptive T cell therapy due to their unique biology and favorable characteristics in the management of cancer. The unique ability of targeting cells in major histocompatibility complex independent manner and recognizing a broader range of antigens has gained a lot of interest by the researchers. As of now, there are no approved gamma delta T therapies but a pool is present in clinical trials. Majority of the candidates belongs to early phase clinical trial which will require about 5-7 years to enter the market.

The encouraging response of the gamma delta T cell therapy in the management of cancer has surged the researchers for the exploiting the role of gamma delta T cells in other diseases also. A number of preclinical studies have been initiated by researchers to identify their role in diabetes, infectious and autoimmune diseases. As per report, it is expected that global gamma T cell therapy will witness huge growth rate in coming years and the market will be flourished with various potential candidates in management of wide range of diseases.

Despite several restraining factors in the growth of market including low physical frequency, high cost of development and stringent regulatory guidelines the overall market will follow a trajectory path. This is mainly due to the rising partnerships and collaborations among the pharmaceutical companies which increases the investment to carry out research and development activities. The major key players operating in the market are Acopedia, Takeda Pharma, TC Biopharma and Adapate Therapeutics which have robust clinical pipeline of gamma delta T cells candidates.

In coming years, the subsequent rise in the prevalence of cancer and the rates at which conventional therapies are failing will possess unmet need for the development of novel therapies which will drive the gamma delta T cell therapy market. Moreover, the exploitation of the therapy in management of other diseases will also propel the growth of marker.

In addition to this, it is analyzed that North America will hold the top position in the global market due to rising geriatric population and increase government initiatives to promote novel therapies. In the forecast period, Europe and Asia-Pacific will also emerge as a potential market due to increase in awareness among the population of the region.

Report Highlights

  • Commercialization Market Potential After Market Launch: > USD 4 Billion

  • Insight on Key Drugs In Research & Development

  • Global Gamma Delta T Cell Cancer Therapy Clinical Trials Insight

  • Gamma Delta T Cell Cancer Therapy In clinical Trials: > 15 Therapies

  • Gamma Delta T Cell Cancer Therapy Market Opportunity By Cancer Type

  • Adopted Approaches for Gamma Delta T Cell Therapy

Competitive Landscape

  • Acepodia

  • Adaptate Therapeutics

  • Adicet

  • Cytomed Therapeutics

  • Gadeta

  • GammaDelta Therapeutics

  • IN8bio

  • Kiromic Biopharma

  • Lava Therapeutics

  • Takeda Pharmaceuticals

  • TC Biopharm

For more information about this report visit https://www.researchandmarkets.com/r/f8rdj4

View source version on businesswire.com: https://www.businesswire.com/news/home/20210518005674/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900